SCHEMBL25375799

SCHEMBL25375799

FC(F)(F)c1ccccc1C=C1CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.59
IL6 P05231 3/20 0.59
MYC P01106 1/20 0.47
MAX P61244 1/20 0.47
NFKB1 P19838 1/20 0.47
CCR3 P51677 1/20 0.43
GRIN2D O15399 2/20 0.43
GRIN3B O60391 2/20 0.43
GRIN1 Q05586 2/20 0.43
GRIN2A Q12879 2/20 0.43
GRIN2B Q13224 2/20 0.43
GRIN2C Q14957 2/20 0.43
GRIN3A Q8TCU5 2/20 0.43
CYP24A1 Q07973 1/20 0.43
MAOB P27338 4/20 0.40
P4HB P07237 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5015224 0.87 TNF (0.51) TNFIL6MYCMAXNFKB1
SCHEMBL4252698 0.79 TNF (0.48) TNFIL6MYCMAXNFKB1
SCHEMBL2973276 0.77 CCR3 (0.44) TNFIL6MYCMAXNFKB1
SCHEMBL2494559 0.75 NFKB1 (0.55) TNFIL6MYCMAXNFKB1
SCHEMBL4163324 0.75 NFKB1 (0.47) TNFIL6MYCMAXNFKB1
SCHEMBL14119823 0.74 TNF (1.00) TNFIL6MYCMAXNFKB1
SCHEMBL14119825 0.74 TNF (1.00) TNFIL6MYCMAXNFKB1
SCHEMBL4157687 0.74 TNF (0.50) TNFIL6MYCMAXNFKB1
SCHEMBL4259286 0.74 GRM5 (0.46) TNFIL6NFKB1MEN1KMT2A
SCHEMBL28354128 0.73 TNF (0.74) TNFIL6MYCMAXNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2025-03-27 US disclosed
EP-4469451-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-12-04 EP disclosed
CN-119032090-A 2-Substituted thiazole HSD17B13 inhibitors and uses thereof 伊尼制药公司 2024-11-26 CN disclosed
WO-2023146897-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2023-08-03 WO disclosed
WO-2023146897-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 TNF 3752/4885IL6 3992/4885MYC 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.